New research reveals that people who come off new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who halt conventional diet and exercise regimens.
Published data in a major health publication points out that while obese individuals can lose a large proportion of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments must be cognizant of the danger of quick rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of recovery implies a return to starting mass in about 18 months.
Analyzing Treatments
The research, which examined 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.
Scientists point out that individuals who shed pounds through lifestyle changes alone typically have a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Quick Regain
Nutrition scientists propose the way of the injections is key to understanding the accelerated regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
Medical guidelines suggest the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, given the likelihood of relapse, the treatment should be considered long-term.
This view is supported by drug manufacturers, who note that the results "emphasize the chronic character of obesity," comparing it to managing conditions like high blood pressure.
User Experiences
Individuals who have stopped the jabs describe a intense resurgence of hunger.
"It was like a switch that goes on and I was suddenly ravenous," described one woman.
This difficulty is exacerbated if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Adoption
Figures show that millions of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is more common among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while the jabs are potent tools for weight loss, they are not a permanent fix and maintained weight loss hinges on integrated lifestyle management.
